[{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"e2eaeeff-423b-47e0-ae9e-fabb69967767","acronym":"NRG-GY033","url":"https://clinicaltrials.gov/study/NCT06169124","created_at":"2023-12-13T21:16:59.860Z","updated_at":"2024-07-02T16:34:27.588Z","phase":"Phase 2","brief_title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","source_id_and_acronym":"NCT06169124 - NRG-GY033","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-10"},{"id":"6da56897-8f08-4a74-9e58-82fd41fa691a","acronym":"ImmunoADAPT","url":"https://clinicaltrials.gov/study/NCT03573648","created_at":"2021-01-18T17:35:04.704Z","updated_at":"2024-07-02T16:35:12.680Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT03573648 - ImmunoADAPT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • Bavencio (avelumab) • Eligard (leuprolide acetate) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-27"},{"id":"07290b42-fecd-4d59-8d89-3c17f5f0e7a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01431391","created_at":"2021-01-18T05:54:50.916Z","updated_at":"2024-07-02T16:37:21.706Z","phase":"Phase 2","brief_title":"Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer","source_id_and_acronym":"NCT01431391","lead_sponsor":"Dendreon","biomarkers":" IFNG • ICAM1","pipe":"","alterations":" ","tags":["IFNG • ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-05-30"},{"id":"eb853216-6770-42ac-b694-08e5c7477e36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588404","created_at":"2021-01-18T12:33:33.544Z","updated_at":"2024-07-02T16:37:30.172Z","phase":"","brief_title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","source_id_and_acronym":"NCT02588404","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" ERG • TMPRSS2","pipe":" | ","alterations":" TMPRSS2-ERG fusion","tags":["ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMPRSS2-ERG fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-28"}]